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Summary To determine whether alterations in oncogenes are associated with tumour progression and
metastasis, DNAs from 32 metastatic tumour samples of different sites in 12 autopsy cases of gastric
carcinomas were analysed for alterations of ERBB, ERBB2, HST1, INT2 and LMYC genes by Southern blot
hybridisation. DNAs from 89 primary gastric carcinomas including 69 advanced carcinomas and 20 early
carcinomas were also examined. In primary tumours, no amplification was detected in early carcinomas, while
amplification of ERBB and ERBB2 genes was detected in one (1.4%) and four (5.8%) out of 69 advanced
carcinomas, respectively. In metastatic tumours, amplification of ERBB gene was detected in three metastatic
tumours (9.4%), and all of them had allelic deletion of the LMYC gene. Regardless of histological type,
amplification of ERBB2 gene was detected in 8 metastatic tumours (25.0%), out of which three tumours had
coamplification of HST1 and INT2 genes. The incidence of ERBB2 amplification in metastatic tumours was
significantly higher than that in primary tumours. These results indicate that multi-alterations in oncogenes
might occur during tumour progression and metastasis of human gastric carcinomas.
Recent evidence indicates that amplification of specific onco-
genes is correlated with tumour stage and prognosis of
neuroblastomas (Tsuda et al., 1988a), breast carcinomas
(Slamon et al., 1987; Varley et al., 1987), and small cell lung
carcinomas (Johnson et al., 1988). Moreover, specific chro-
mosome abnormalities have also been found in a number of
human cancers (Yokota et al., 1987; Baker et al., 1989; Lee
et al., 1989). However, activation of proto-oncogenes in gas-
tric carcinomas is low compared to colonic and pancreatic
carcinomas (Forrester et al., 1987; Smit et al., 1988).
Loss of chromosomal heterozygosity is also infrequently
found in gastric carcinomas even at chromosomal loci fre-
quently deleted in other tumours, and little is known about
genetic changes that are associated with metastasis of gastric
carcinomas. We have demonstrated previously that ampli-
fication of ERBB and ERBB2 genes is detected in 2.7% and
5.4% of primary gastric carcinomas, respectively (Yoshida et
al., 1989). To ascertain whether alteration of oncogene plays
an important role in tumour progression and metastasis,
Southern blot analyses were conducted on DNAs extracted
from samples of early, advanced and metastatic human gas-
tric carcinomas.
Materials and methods
Tissues
A total of 121 gastric carcinomas including 20 early tumours,
69 advanced tumours, and 32 metastatic tumours were
analysed. Early carcinomas and 64 cases of advanced
primary tumours were resected at surgery and 5 primary and
32 metastatic tumours were obtained at autopsy. The samples
of early carcinomas were formalin-fixed and paraffin-embed-
ded. In advanced and metastatic tumours, a small piece of
each tissue was immediately frozen in liquid nitrogen as soon
as the tumour tissues were removed; the diagnosis was
confirmed microscopically on cryostat sections. The autopsy
samples are summarised in Table I.
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Southern blot analysis
High molecular weight DNAs were prepared using the
phenol-chloroform method after treatment with sodium do-
decyl sulphate (SDS) and proteinase K. DNAs were digested
with EcoRI or BamHI, and 10iLg of completely digested
DNAs was electrophoresis on 0.8% agarose gel. After elec-
trophoresis, DNAs were denatured, neutralised and transfer-
red to nitrocellulose filters according to the method of
Southern (Southern, 1975). The filters were hybridised under
stringent conditions with 32P-labelled probes. After hybridisa-
tion, filters were washed and exposed to Kodak XAR-5 films.
The same filters were hybridised repeatedly with probes for
several oncogenes to exclude the possibility that the differ-
ence in the intensities of the bands in different lanes was due
to difference in the amounts of DNAs loaded on agarose
gels. The levels of amplification were determined by densi-
tometry and the sum of the densitometric signals of all the
bands was taken.
Slot blot analysis
DNAs were extracted from formalin-fixed and paraffin-
embedded tissues of 20 early gastric carcinomas and one
advanced gastric carcinoma whose metastatic tumours had
amplification of ERBB2, HST1, and INT2 genes. Sections of
20Itm in thickness were cut from the blocks using a micro-
tome and these sections were collected. DNAs were extracted
following the methods of Goelz et al. (1985) or Dubeau et al.
(1986). Ten ILg of the DNA was dissolved in 0.4 M sodium
hydroxide, and TE (10 mM tris hydroxymethyl amino-
methane and 1 mM ethylene diaminetetraacetic acid (EDTA)
pH 7.4) was added to make 50pAl of the solution. The sam-
ples were incubated for 10 minutes at 37°C, treated with an
equal volume of 2 M ammonium acetate and applied to a
nitrocellulose filter. Filters were baked at 80°C for 2 hours
under vacuum. The procedure of hybridisation was the same
as that of Southern blot analysis as described above.
DNA probes
Probe C, a 0.79 kbp EcoRI-EcoRI fragment of the HST1
gene was kindly provided by Dr Sakamoto (Sakamoto et al.,
1986). pCER204, a 1.6 kbp EcoRI-EcoRI fragment of
ERBB2 gene was kindly provided by Dr Yamamoto (Yama-
moto et al., 1986). A 0.9 kbp SacI-SacI fragment of the
INT2 gene, a 1.8 kbp SmaI-EcoRI fragment of the LMYC
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Table I Human tissue samples analysed for oncogene alteration ofgastric carcinoma in
12 autopsy cases
Oncogene alterations
Primary
tumour
_b
NEe
NE
ERBB28
Amp x 8
Metastatic tumours Metastatic sites
ERBB2 Ampc x 16d Lung
ERBB Amp x 16
LMYC Del'
ERBB2
Amp x 16-36
HSTI Amp x 4-8
INT2 Amp x 4-8
NE
NE
ERBB2
Amp x 16
NE
NE
ERBB2 Amp x 16
3 lymph nodes
Liver, pancreas, lymph node
Intestine, lymph nodes
3 lymph nodes
2 lymph nodes
Abdominal wall, pancreas,
2 intestine
3 lymph nodes
Spleen, pancreas, abdominal
wall, intestine
Liver, 2 lymph nodes
2 lymph nodes
Ovary, intestine
aAccording to thecriteria ofJapanese Research SocietyforGastricCancer(1985). Well,
well differentiated adenocarcinomaincludingpapillaryandtubularadenocarcinoma; por,
poorly differentiated adenocarcinoma; sig, signet ring cell carcinoma. bNo oncogene
alterations. cAmplification. dDegree ofamplification. eNot examined. fDeletion. 9DNAs
were extracted from paraffin embedded primary tumour at first operation.
gene and a 2.4 kbp ClaI-ClaI fragment of the ERBB gene
were obtained from Japanese Cancer Research Resources
Bank (JCRB).
Results
Southern blot analysis
Figures I and 2 show the results of Southern blot analyses in
metastatic tumours of gastric carcinomas. Probes used were
ERBB, ERBB2, INT2, HSTI and LMYC genes. Each lane
contained 10 lg of EcoRI or BamHI digested DNA. Almost
equal intensity of the 6.6-kilobase EcoRI fragment and 8.0-
kilobase BamHI fragment of LMYC gene indicated that each
lane contained almost equal amounts of total DNA. In case
3, ERBB gene was amplified in three different metastatic sites
of the liver, pancreas and lymph node. All of the same
tumours had allelic deletion of LMYC gene (Figure la). On
a b
3 1 9
N H PLy NLuT NTPS A
-23.1 -23.1
-9.4 ~ ~ ~ ~ ~ ~~
ER ERBB2 44
-2.0 -2.3
l448v -10.0
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Figure 1 Oncogene alteration in metastatic tumours of gastric
carcinomas. 10 fg of EcoRI digested DNA was subjected to
Southern blot hybridisation with ERBB and LMYC genes (a),
ERBB2 and LMYC genes (b). The head numbers show case
number. N stands for normal tissues, H for metastatic tumour of
liver, P for metastatic tumour of pancreas, Ly for metastatic
tumour of lymph node, Lu for metastatic tumour of lung, T for
primary tumour, S for metastatic tumour of spleen, A for metas-
tatic tumour of abdominal wall and I for metastatic tumour of
intestine. The numbers on the right show kilobase pair. In case 3
(a), ERBB gene was amplified in metastatic tumours of liver (H),
pancreas (P) and lymph nodes (Ly). In case 1 (b), ERBB2 gene
was amplified in metastatic tumour of lung (Lu), but not in
primary tumour (T). In case 9 (b), ERBB2 gene was amplified in
primary tumour and all metastatic tumours.
the genomic DNA digested in EcoRI, LMYC showed 10.0-
and 6.6-kilobase allelic fragments in normal tissue, but in
metastatic tumours of the liver, pancreas and lymph node the
intensity of 10.0 kb band was deleted or decreased. The
remaining hybridisation signal of the deleted allele in this
case was presumably due to contamination by normal cells,
or heterogeneity of tumour cells. Especially, the metastatic
tumour of the pancreas seemed to have more contamination
of normal cells than other metastatic tumours, as the degree
of ERBB amplification in this tumour was lower than other
metastatic tumours, and the remaining hybridisation signal of
LMYC 10.0 kb allele was higher than other metastatic
tumours. The histological type of this case was well differ-
entiated tubular adenocarcinoma. In case 1, ERBB2 gene was
amplified in lung metastatic tumour but not in primary
tumour, and in case 9, ERBB2 gene was amplified in primary
and all metastatic tumours of the pancreas, spleen,
abdominal wall and intestine (Figure lb). The histological
type of case 1 and case 9 was poorly differentiated adenocar-
cinoma and signet ring cell carcinoma, respectively. They did
not contain tubular type adenocarcinoma. In case 5, ERBB2
gene was amplified in three metastatic tumours of the lymph
nodes (Figure 2a) whose histological type was well differ-
entiated adenocarcinoma. Interestingly, all of the tumours of
case 5 had co-amplified INT2 and HSTI genes (Figure 2b).
In INT2 probe SS6 hybridised to an 8.4-, 5.6-, and 2.8-kilo-
base allelic fragment. In the DNA from the patient with the
amplified sequences, BamHI digestion showed that the 8.4-kb
allele was amplified and the 5.6 and 2.8 kb allele was normal.
All of the same tumours had amplification of HST1 gene.
Photodensitometrical analysis demonstrated that the degree
of ERBB gene amplification was about 8 to 16 fold in case 3,
that of ERBB2 gene was about 16 to 32 fold in case 1 and
case 9, and that of INT2 and HST1 genes was about 4 to 8
fold in case 5.
In primary tumours, we have already demonstrated that
ERBB and ERBB2 genes were amplified in one and two out
of 31 advanced gastric carcinomas (Yoshida et al., 1989). In
this study we examined 38 additional cases of advanced
gastric carcinoma, including 32 fresh samples of surgical
cases, one paraffin-embedded tissue of a surgical case and 5
fresh samples of autopsy cases. We found two cases of
ERBB2 amplification, i.e. autopsy case 9 (Figure lb) and
case 5 of paraffin embedded surgical case (Figure 3).
Therefore, the frequency of ERBB and ERBB2 gene ampli-
fication in primary tumours was one (1.4%) and 4 (5.8%)
out of 69 primary tumours, respectively.
Case
no.
2
3
4
5
Histological
typea
por
por
well
sig
well
6 sig
7 well
8 por
9 sig
10 por
11 por
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examined 20 cases of formalin-fixed and paraffin-embedded
tissues of early gastric carcinomas for slot blot analyses,
amplification of ERBB and ERBB2 gene could not be
detected. Figure 4 is a representative result of slot blot
analyses in early gastric carcinomas. Judging from the inten-
sities of P-actin, ERBB and ERBB2 genes were not amplified
in these cases.
-2.3 HST1 W -8.7
-10.0
LMYC -6.6 LMYC -8.0
Eco RI Bam Hi
Figure 2 Oncogene alterations in metastatic tumours of gastric
carcinoma, case 5. 10 fig of EcoRI digested DNA was hybridised
with ERBB2 and LMYC genes (a), and 10 1sg of BamHI digested
DNA was hybridised with INT2, HSTI and LMYC genes. N
stands for normal tissue and Lyl-3 for metastatic tumours from
different sites of lymph nodes. The numbers on the right show
kilobase pair. ERBB2 gene was amplified in all metastatic
tumours of lymph nodes (a). And all of the same tumour had
amplification of INT2 and HSTI gene (b).
Slot blot analyses
Figure 3 shows the results of slot blot analyses in primary
tumour of case 5 which showed metastatic tumours with
coamplification of ERBB2, HST1, and INT2 genes (Figure
2). The sample DNAs were extracted from formalin-fixed
and paraffin-embedded tissues. The extracted DNAs were not
suitable for southern blot analysis, because of the fragmenta-
tion of sample DNAs, but could be used for slot blot
analysis. N lane contained 10 fig DNAs from normal
mucosa. T lane contained 10 Lg DNAs from tumour speci-
men, which were diluted 2 fold, 4 fold, and 8 fold. Judging
from the intensities of P-actin, ERBB2 gene was amplified
about 8 fold, whereas INT2 and HST1 genes were not
amplified. In case 3, we also tried to extract DNAs from
primary tumours and examined whether primary tumour had
amplification of ERBB gene. However, DNAs could not be
extracted because of the long period of fixation. Although we
Incidence of oncogene amplification
We summarised the incidence of oncogene amplification in
early, advanced and metastatic tumour of gastric carcinomas
(Table II). In early gastric carcinomas, we could not detect
ERBB, ERBB2, HST1 and INT2 gene amplification. In
advanced primary gastric carcinomas, the incidence of ERBB
and ERBB2 gene amplification was very low (1.4% and
5.8%), and HST1 and INT2 gene was not amplified. On the
other hand, in metastatic tumour of gastric carcinomas, the
incidence of these gene amplifications was significantly higher
than that of early and advanced primary gastric carcinomas.
Discussion
There are two genes related to the viral erbB gene. One is
ERBB which is similar to the gene for the epidermal growth
factor receptor (EGFR) and the other is ERBB2 which
encodes a receptor like protein (Yamamoto et al., 1986). We
have immunohistochemically demonstrated that expression of
EGFR is detected in 3.8% of early gastric carcinomas and in
34.4% of advanced carcinomas and that it is correlated with
the depth of tumour invasion and tumour staging (Tahara et
al., 1986; Yasui et al., 1988). Moreover, we have found that
the incidence of ERBB and ERBB2 gene amplification is
1.4% and 5.8% in primary advanced gastric carcinomas,
respectively.
In the present study, the frequency of ERBB and ERBB2
gene amplification in metastatic gastric carcinomas of
autopsy cases was 9.4% and 25.0%, respectively, which was
evidently higher than that of advanced primary carcinomas.
Moreover, we did not detect amplification of these genes in
early gastric carcinomas (Table II). These results strongly
indicate that amplification of ERBB and ERBB2 genes might
occur during the course of progression and metastasis.
a b c
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,B-actin
N
T
N
T
N
T
N
T
Figure 3 Slot blot analyses in a primary tumour of case 5. N
stands for normal tissue and T for tumour tissue. N lane con-
tained 10 gg of DNAs extracted from paraffin blocks, T lane
contained 10 Lg of DNAs, and diluted 2 fold, 4 fold and 8 fold.
Probes used were ERBB2, INT2, and HSTI. In this case, ERBB2
gene was amplified about 8 fold, but INT2 and HST1 gene was
not amplified. Judging from the intensities of P-actin, almost the
same amounts of DNAs were spotted on to the filter at I fold N
and 1 fold T.
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Figure 4 Slot blot analyses in early gastric carcinomas using
ERBB (a), ERBB2 (b) and P-actin (c) genes as probes. Numbers
on the left show case numbers. There was no amplification of
ERBB and ERBB2 gene in these cases.
Table II Incidence of oncogene amplification in early, advanced and
metastatic gastric carcinomas
Cases with oncogene amplification
Total
Materials cases ERBB ERBB2 HSTand INT2
Early 20 0 0 0
carcinoma (0.0%) (0.0%) (0.0%)
Advanced 69 1 4 0
carcinoma (1.4%) (5.8%)b (0.0%)c
Metastatic 32a 3 8 3
carcinoma (9.4%) (25.0%)b (9.4%)C
a32 metastatic tumour samples from different sites in 12 patients.
bSignificantly different (P<0.01, x2 test). cSignificantly different
(P<0.05, X2 test).
b a
ERBB2
5
N Ly Ly Ly
1 2 3
-23;1
-9.4
-6.7
-4.4
5
N Ly Ly Ly
1 2 3
INT2 -8.4
-5.6
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ERBB2 gene amplification is well known to occur selec-
tively in tubular adenocarcinoma of the stomach (Yokota et
al., 1988a). However, in the present study, ERBB2 gene was
amplified not only in well differentiated tubular adenocar-
cinoma, but also in poorly differentiated adenocarcinoma or
signet ring cell carcinoma of metastatic tumours. In addition,
metastatic tumours were associated with multiple alterations
of oncogenes. To our knowledge, they are the first reports
showing ERBB amplification and LMYC deletion, or
ERBB2, INT2 and HST1 gene coamplification in metastatic
tumours of gastric carcinoma.
The LMYC gene maps to chromosome 1 at band p32, and
this locus is frequently lost in endocrine neoplasia (Mathew
et al., 1987). Loss of heterozygosity (LOH) on chromosome
lp has been observed in two of 12 gastric carcinomas in
surgical cases (Wada et al., 1988). In the present study, allelic
deletion of LMYC gene was detected in three of 32 metas-
tatic tumours, and its incidence was almost the same as that
of LOH of chromosome lp reported by Wada et al. (1988).
However, Fey et al. (1989) recently reported that other loci
such as chromosome 1 at band q21-24 and chromosome 12
at band q24 were frequently lost in gastric carcinomas. Fur-
ther investigations of LOH are necessary to determine any
correlation between LOH and incidence of gastric carcin-
omas.
The HST1 gene, first isolated from gastric carcinoma by
NIH3T3 transfection assay, is frequently amplified in
squamous cell carcinoma of the oesophagus or head and
neck, and is usually associated with INT2 gene amplification,
because these two genes are mapped to the same loci of
chromosome 11 at band q13 (Wada et al., 1989). We have
detected HST1 and INT2 gene coamplification in 50% of
primary tumours and all of the metastatic tumours of oeso-
phageal squamous cell carcinomas. However, this could not
be detected in primary gastric carcinomas (Tsuda et al.,
1988b, 1989). Interestingly, we detected HST1 and INT2
coamplification in three metastatic tumours of a gastric car-
cinoma with amplified ERBB2 genes. Moreover, the primary
tumour of this case had no amplification of HST1 and INT2
genes, whereas ERBB2 gene was amplified.
There are two possible explanations for the discrepancy of
oncogene amplification between primary and metastatic
tumours. One is that primary tumour contained a small
fraction of the cells with amplified sequence of oncogenes
which had selective advantage to progression or metastasis
(Yokota et al., 1988b; Wahl, 1989). The other is that the
oncogene amplification was not an initiating event of car-
cinogenesis, and they occurred as the results of response to
tumour progression and metastasis (Alitalo, 1987; Yokota et
al., 1988b). It is very difficult to conclude at present whether
amplification contributes to metastasis or is the result of
response to other events. However, recent evidence indicates
that other oncogene alterations and inactivation of tumour
suppresser genes are detected in the early stages of carcinoma
development. In colorectal carcinoma, point mutation of ras
gene and LOH of chromosome 5 occur in the early stage of
tumour or adenoma, and LOH of chromosome 17, 18 occurs
in advanced tumours (Vogelstein et al., 1988). In lung car-
cinomas, LOH of 3, 13 and 17 is found in the early stage of
tumours and amplification of myc family gene is detected in
advanced carcinomas (Yokota et al., 1987, 1988b). These
results support the hypothesis of multistep carcinogenesis
including mutation as the first step, loss of heterozygosity at
the second step, and oncogene amplification at the final step
(Land et al., 1983; Barbacid, 1987; Nicolson et al., 1987;
Yokota et al., 1987, 1988b; Green, 1988). Moreover, our
recent results indicate that overexpression of several tumour
autocrine growth factors in primary tumours occurs regard-
less of gene amplifications (Yoshida et al., 1990a,b). Marco et
al. (1989) also demonstrated the important role of TGF-a
and EGFR on the cell transformation. These results suggest
that hyperproduction of growth factor by tumour cells may
occur before gene amplification. At the terminal stage of
gastric carcinoma with high malignant condition, hyperpro-
duction of tumour autocrine growth factors might result in
multisite metastases, leading to amplification of oncogenes.
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